STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIP
  4. [Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

ANI Pharma CFO sells 2,850 shares under 10b5-1

After the Aug. 31 sale under a Rule 10b5-1 plan, he still directly holds 171,843 shares of ANI common stock.

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) disclosed that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on 2026-08-31 at a weighted average price of $72.80 per share, in trades ranging from $71.89 to $73.36, pursuant to a Rule 10b5-1 trading plan. Following this sale, he directly holds 171,843 shares of ANI common stock.

Positive

  • None.

Negative

  • None.
Insider CAREY STEPHEN P.
Role SVP & CFO
Sold 2,850 shs ($207K)
Type Security Shares Price Value
Sale Common Stock F1, F2 2,850 $72.80 $207K
Holdings After Transaction: Common Stock — 171,843 shares (Direct)
Footnotes (2)
  1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
  2. F2. The shares were sold in multiple trades at prices ranging from $71.89 to $73.36. The price reported above reflects the weighted average sales price.
Shares sold 2,850 shares Common stock sold by SVP & CFO Stephen P. Carey on 2026-08-31
Weighted average sale price $72.80 per share Average price for 2,850 ANIP shares sold on 2026-08-31
Sale price range $71.89–$73.36 per share Multiple trades comprising the 2,850-share sale
Shares owned after transaction 171,843 shares Direct ANIP common stock holdings of Stephen P. Carey after the sale
Rule 10b5-1 plan adoption date March 6, 2026 Adoption date of Stephen P. Carey’s trading plan covering these sales
Net insider share change -2,850 shares Net shares sold in this Form 4, per transaction summary
Rule 10b5-1 trading plan regulatory
"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"The price reported above reflects the weighted average sales price."
open market or private transaction market
"transaction_code_description: Sale in open market or private transaction"

FAQ

What insider transaction did ANIP report for Stephen P. Carey?
ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on 2026-08-31 at a weighted average price of $72.80 per share in open-market or private transactions.

Was the ANIP insider sale by Stephen P. Carey under a Rule 10b5-1 plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Stephen P. Carey on March 6, 2026, indicating the trades were pre-arranged under that plan.

What price range did Stephen P. Carey’s ANIP share sales cover?
The 2,850 ANIP shares sold by Stephen P. Carey on 2026-08-31 were executed in multiple trades at prices ranging from $71.89 to $73.36 per share, with a reported weighted average price of $72.80.

How many ANIP shares does Stephen P. Carey hold after the reported sale?
After selling 2,850 shares on 2026-08-31, Stephen P. Carey directly holds 171,843 shares of ANI Pharmaceuticals common stock, as reported in the Form 4 filing.

What transaction code was used for Stephen P. Carey’s ANIP stock sale?
The transaction was reported with code S, which the filing describes as a sale in open market or private transaction of 2,850 shares of ANI Pharmaceuticals common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAREY STEPHEN P.
(Last)(First)(Middle)
C/O ANI PHARMACEUTICALS, INC.
104 CARNEGIE CENTER, SUITE 300
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP & CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026S(1)2,850D$72.8(2)171,843D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. The shares were sold in multiple trades at prices ranging from $71.89 to $73.36. The price reported above reflects the weighted average sales price.
Remarks:
/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook09/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR